Arthritis Ra Articles & Analysis
8 articles found
Another VHH domain binds to human serum albumin (HSA), and the drug is indicated for rheumatoid arthritis (RA). Ozoralizumab was developed by Ablynx, and Taisho obtained the development authorization from Japan. ...
Abstract Background: Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic inflammation of synovial joints. ...
Cytokine Involvement in Rheumatoid Arthritis (RA) RA, an immune-related polyarticular inflammatory disorder, involves a spectrum of cytokines, including IL-1B, IL-6, IL-12, IL-15, and TGF-β. ...
Clinical Applications of MMP-3 MMP-3 and Rheumatoid Arthritis (RA) Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized by synovial cell proliferation and infiltration of lymphocytes, leading to destruction of joint cartilage and bone erosion. Previous studies have shown that MMP-3 levels in the serum ...
In patients with multiple sclerosis (MS), rheumatoid arthritis, and acute coronary syndrome, the increase in IL-17A concentration is associated with systemic inflammation parameters [3]. ...
The complement system is involved in the progression of many diseases, and complement activation is associated with several common autoimmune diseases, such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), ophthalmic diseases such as uveitis and glaucoma, renal diseases including C3 glomerulopathy, atypical hemolytic uremic syndrome and IgA ...
Genetics (i.e., mutations) are considered to be the main factor predisposing to the etiology of rheumatoid arthritis (RA), but they account for only a few changes in RA disease risk, and in contrast to genetics, the environment may have an important impact on epigenetic properties associated with disease etiology. Recently, in a study published ...
ABBV-3373, which is being developed by AbbVie, is an ADC drug composed of adalimumab and glucocorticoid receptor modulator (GRM) for the potential treatment of rheumatoid arthritis (RA). According to its Phase III experimental data released in June 2020, compared with adalimumab, ABBV-3373 could bring a more significant improvement in the DAS28 CRP score in the ...